Tilray Brands Inc. (NASDAQ:TLRY) is accelerating its global push across healthcare, cannabis, and beverages, but investor sentiment turned cautious after the company unveiled a $180 million at-the-market equity program that raised dilution concerns and pressured shares on Wednesday.
The company acquired the Lyphe Group to strengthen its U.K. medical platform and build a vertically integrated healthcare ecosystem. Terms of the deal were not disclosed.
Tilray is also scaling its beverage business following the acquisition of BrewDog, targeting international expansion and aiming for cash-flow positivity by 2027. It plans to launch Hi*Ball Energy in the U.K. next month.
In the U.S., the company is positioning for potential medical cannabis rescheduling. To fund growth, Tilray filed a $180 million at-the-market equity program managed by Jefferies LLC and partners.
As of the end of its third fiscal quarter on February 28, 2026, Tilray Brands reported a cash, restricted cash, and marketable securities balance of $264.8 million.
Technical Analysis
Tilray is currently trading within the lower range of its 52-week spectrum, which has seen a high of $23.20 …
This post was originally published here
